← All trials
NCT02574910
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2016
- Primary completion
- Dec 1, 2017
- Completion date
- Jan 1, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 36
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- The University of Texas, DallasLead sponsor
- University of MichiganCollaborator
- University of Southern CaliforniaCollaborator
- Feinstein Institute for Medical ResearchCollaborator
- National Institutes of Health (NIH)Collaborator
- The University of Texas, DallasOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.